BariatricSource

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of a Phase 2b trial for Empatic™ on Wednesday, September 30, 2009 before the markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time.

Orexigen management will host the call and webcast to discuss the results of this clinical trial and answer questions. The live call may be accessed by phone by calling (800).884.5695 (domestic) or (617).786.2960 (international), participant code 64389662. The webcast can be accessed live on the investor relations section of the Orexigen web site, and will be archived for 14 days following the call.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave, has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product candidate, Empatic, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.